Citations

Clear

6055 citation(s) found for "Vu, Peter".

The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement
Leibovich, Bradley C. , George, Daniel J. , Pickering, Lisa , Blackmur, James Peter , Jones, James O. , Laird, Alexander , Warren, Anne Y. , George, Daniel J. , Rosa, Salvatore La , Stewart, Grant D.

Mayo Clinic

Medicom Conference Report Proceedings of the 2024 IKCS: Europe Symposium | October 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55788/bba1f0bd Get It

Circulating miRNAs and Machine Learning for Lateralizing Primary Aldosteronism
Vékony, Bálint , Herold, Zoltán , Fekete, János Tibor , Gruber, Sven , Kürzinger, Lydia, Parasiliti‐Caprino, Mirko , Bioletto, Fabio , Szücs, Nikolette , Doros, Attila , Szeredas, Balint , Nazri, Siti Khadijah Syed Mohammed , Fell, Vanessa , Azizan, Elena , Beuschlein, Felix , Herold, Zoltan , Fekete, János , Ceccato, Filippo , Gruber, Sven , Bioletto, Fabio , Szücs, Nikolette , Szeredás, Bálint Kende , Syed Mohammed Nazri, Siti Khadijah , Fell, Vanessa , Bassiony, Mohamed, Dank, Magdolna , Azizan, Elena Aisha , Bancos, Irina , Beuschlein, Felix , Igaz, Peter , Parasiliti-Caprino, Mirko , Nyírő, Gábor , Ceccato, Filippo , Bassiony, Mohamed A. A. , Bancos, Irina , Igaz, Péter

Mayo Clinic

Hypertension | October 17, 2024 | Volume: 81 | Issue: 12 | Pages: 2479-2488

10.1161/hypertensionaha.124.23418 | PMID 39417220 Get It

BACKGROUND: Distinguishing between unilateral and bilateral primary aldosteronism, a major cause of secondary hypertension, is crucial due to different treatment approaches. While adrenal venous sampling is the gold standard, its invasiveness, limited availability, and often difficult interpretation pose challenges. This study explores the utility of circulating microRNAs (miRNAs) and machine learning in distinguishing between unilateral and bilateral forms of primary aldosteronism. METHODS: MiRNA profiling was conducted on plasma samples from 18 patients with primary aldosteronism taken during adrenal venous sampling on an Illumina MiSeq platform. Bioinformatics and machine learning identified 9 miRNAs for validation by reverse transcription real-time quantitative polymerase chain reaction. Validation was performed on a cohort consisting of 108 patients with known subdifferentiation. A 30-patient subset of the validation cohort involved both adrenal venous sampling and peripheral, the rest only peripheral samples. A neural network model was used for feature selection and comparison between adrenal venous sampling and peripheral samples, while a deep-learning model was used for classification. RESULTS: Our model identified 10 miRNA combinations achieving >85% accuracy in distinguishing unilateral primary aldosteronism and bilateral adrenal hyperplasia on a 30-sample subset, while also confirming the suitability of peripheral samples for analysis. The best model, involving 6 miRNAs, achieved an area under curve of 87.1%. Deep learning resulted in 100% accuracy on the subset and 90.9% sensitivity and 81.8% specificity on all 108 samples, with an area under curve of 86.7%. CONCLUSIONS: Machine learning analysis of circulating miRNAs offers a minimally invasive alternative for primary aldosteronism lateralization. Early identification of bilateral adrenal hyperplasia could expedite treatment initiation without the need for further localization, benefiting both patients and health care providers.
Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity
Lyu, Yu-Xuan, Wilczok, Dominika , Antebi, Adam , Vojta, Aleksandar , Stolzing, Alexandra , Moskalev, Alexey , Georgievskaya, Anastasia , Maier, Andrea B. , Olsen, Andrea, Groth, Anja , Brunet, Anne , Jamil, Aisyah, Kulaga, Anton , Bhatti, A.R., Yaden, Benjamin C., Djordjevic, Boris, Chen, Chieh, Huang, Christine Yuan, Chen, Danica , Sołdacki, Dariusz, Meyer, David H. , Chini, Eduardo N. , Morgen, Eric , Vernet, Erik , Pinilla, Estefano, Mercken, Evi M. , Finger, Fabian , Kuipers, Folkert , Gyülvészi, Gábor, Zmudze, Garri, Blander, Gil , Pincus, Harold A., McClure, Joshua, Kirkland, James L. , Peyer, James , McLaughlin, Jerry L., Mannick, Joan B. , Betts-LaCroix, Joe , Sedivy, John M. , Speakman, John R. , Shlain, Jordan, Maltzahn, Julia von , Andreasson, Katrin I. , Moody, Kelsey , Fortney, Kristen , Niedernhofer, Laura J., Veenhoff, Liesbeth M. , Melton, Lisa , Quarta, Marco , Koval, Maria, Marinova, Maria B., Hamalainen, Mark, Unfried, Maximilian , Ringel, Michael S. , Filipović, Miloš R. , Topors, Mourad, Mitin, Natalia , Roy, N. N., Pintar, Nika, Barzilai, Nir , Binetti, Paolo, Kohlhaas, Paul, Rubin, Paul , Kamya, Petrina, Muñoz‐Cánoves, Pura , Конрад, Р. , Ripa, Roberto , Mansukhani, Robin, Büttner, Sabrina , Brunemeier, Sebastian, Jakimov, Sergey, Rosenzweig‐Lipson, Sharon, Tsai, Shih‐Yin , Rando, Thomas A. , Peterson, Timothy R. , Woods, Tina , Wyss‐Coray, Tony , Finkel, Toren , Strauss, Tzipora , Longo, Valter D. , Sorrentino, Vincenzo , Sebastiano, Vittorio , Li, Wenbin , Suh, Yousin , Niedernhofer, Laura J. , Lu, Yuxuan , Passos, Joao, Niedernhofer, Laura J , Wyss-Coray, Tony , Bakula, Daniela , Lyu, Yu-Xuan, Fu, Qiang , Ying, Kejun , King, Aaron, Olsen, Andrea, Simon, Anna Katharina , Jamil, Aisyah, Bhatti, Asif, Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Huang, Christine Yuan, Correll, Christoph Ulrich , Murphy, Coleen Tara , Ewald, Collin Y. , Valenzano, Dario Riccardo , Erritzøe, David , Sinclair, David , Teeling, Emma C. , Verdin, Eric , Pinilla, Estéfano , Fang, Evandro Fei , Bischof, Evelyne Y. , Pun, Frank W. , Civiletto, Gabriele , Justice, Jamie N. , Vijg, Jan , Gruhn, Jennifer R. , McLaughlin, Jerry, Passos, João F. , Baur, Joseph A. , Shlain, Jordan, Palikaras, Konstantinos , Rasmussen, Lene Juel , Ferrucci, Luigi , Koval, Maria, Topors, Mourad, Roy, Nawal, Pintar, Nika , Singh, Parminder Pal , Robbins, Paul D. , Fedichev, Peter O. , Cabo, Rafael de , Faragher, Richard , Konrad, Rob, Wickström, Sara A. , Brunemeier, Sebastian A., Luo, Shan , Dimmeler, Stefanie , Gladyshev, Vadim N. , Dwaraka, Varun B. , Gorbunova, Vera , Acosta-Rodríguez, Victoria A. , Suh, Yousin , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.18632/aging.206135 | PMID 39418098 Get It

The canine homolog of human receptive speech area responds selectively to social reinforcement
Miller, Kai J. , Lampert, F. , Kim, Inyong , Ince, Nuri F. , Hermes, Dora, Lampert, Frederik, Mívalt, Filip , Kim, Jiwon W. , Křemen, Václav , Baker, Matthew , Boom, Max van den , Hermes, Dora , Coenen, Volker Arnd , Schalk, Gerwin , Brunner, Peter , Worrell, Gregory A.

Mayo Clinic

No container title available | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5183241/v1 Get It

Abstract Studying mammalian brain function aids our understanding of human brain evolution. We implanted a beagle with a prototype human neuromodulation platform that measures activity from the brain surface. One year later, a set of simple sensory tasks was performed, finding visual and somatosensory representation in the canine homologs of the expected areas in humans. Surprisingly, the canine anterior ectosylvian gyrus, which is anatomically homologous to human receptive speech areas, was selectively active during independent social reinforcement tasks. This suggests that human speech understanding may have evolved from more general mammalian brain structures that are specialized for social reinforcement.
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Mattison, Ryan J. , Abdelmessieh, Peter, Burke, Patrick W. , DeAngelo, Daniel J., Dinner, Shira, Fathi, Amir T. , Haddadin, Michael , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Long, Meixiao, Luger, Selina M. , Mangan, James K. , Massaro, Stephanie, May, William , Park, Jae H. , Schwartz, Marc S. , Shami, Paul J. , Tomlinson, Benjamin , Webster, Jonathan , Stehman, Katie, Shah, Bijal , Abboud, Ramzi , Aldoss, Ibrahim , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Jonas, Brian A. , Logan, Aaron C , Oluwole, Olalekan O. , Przespolewski, Amanda , Rangaraju, Sravanti , Saygin, Caner , Schwartz, Marc, Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 563-576

10.6004/jnccn.2024.0051 | PMID 39413812 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.
Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer , Adler, Jeremy, Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Xiangfeng , Chen, Wenli , Higgins, Peter D R , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Bastidas, Monique , Firestine, Ann M. , Craig, Riley, Boccieri, Margie , Long, Millie D. , Kastl, Arthur J , Farraye, Francis A , Long, Millie D , Kappelman, Michael D , Brenner, Erica J. , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Kappelman, Michael D.

Mayo Clinic

Inflammatory Bowel Diseases | October 16, 2024 | Volume: 31 | Issue: 7 | Pages: 1797-1805

10.1093/ibd/izae225 | PMID 39412147 Get It

Abstract Background Children with inflammatory bowel disease (IBD) may have diminished serologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and increased risk for subsequent severe coronavirus disease 2019 (COVID-19) infection. We sought to describe outcomes among those who developed SARS-CoV-2 infection following vaccination, characterize SARS-CoV-2 antibodies 1 year post-vaccination, and identify factors associated with durable serologic response. Methods We recruited children with IBD who received ≥2 doses of SARS-CoV-2 vaccine and prospectively collected data on (1) demographics, IBD characteristics, and therapy and (2) SARS-CoV-2 vaccination, testing, and infection symptoms. Serum was obtained for measurement of anti-receptor-binding domain IgG antibodies following a 2-part immunization at 12 and 52 weeks. Results We enrolled 298 participants (mean age 11.9 ± 3.82, 50% female, 67% Crohn’s disease). Symptomatic COVID-19 infection after vaccination occurred in half of the participants, although only 2 (1%) required hospitalization. Anti-tumor necrosis factor alpha (TNF-α) was associated with higher likelihood of symptomatic COVID-19 infection, with an adjusted hazard ratio of 2.7 (95% CI, 1.5-5.0; P = .001). Nearly all participants (99%) had detectable antibody at Week 52. Children aged 1-5 years had lower 52-week antibody level compared to older children (P = .04), as did those on anti-TNF-α therapy (P = .007) and those who received only 2 vaccine doses prior to Week 52 (P < .001). Conclusions SARS-CoV-2 vaccination provides lasting serologic response and protection against severe COVID-19 for most children with IBD, despite the use of lower vaccine doses in younger children and wide-ranging classes of immunosuppressive therapies.
Artificial intelligence evaluation of electrocardiographic characteristics and interval changes in transgender patients on gender-affirming hormone therapy
Adel, Fadi , Sang, Philip, Walsh, Connor , Maheshwari, Arvind , Cummings, Paige , Mangold, Kathryn, Davidge‐Pitts, Caroline , López-Jiménez, Francisco , Friedman, Paul A. , Adel, Fadi W , Davidge-Pitts, Caroline , Lopez-Jimenez, Francisco , Friedman, Paul A , Mankad, Rekha , Attia, Zachi I. , Noseworthy, Peter A. , Mankad, Rekha

Mayo Clinic

European Heart Journal - Digital Health | October 15, 2024 | Volume: 6 | Issue: 1 | Pages: 55-62

10.1093/ehjdh/ztae076 | PMID 39846073 Get It

Abstract Aims Gender-affirming hormone therapy (GAHT) is used by some transgender individuals (TG), who comprise 1.4% of US population. However, the effects of GAHT on electrocardiogram (ECG) remain unknown. The objective is to assess the effects of GAHT on ECG changes in TG. Methods and results Twelve-lead ECGs of TG on GAHT at the Mayo Clinic were inspected using a validated artificial intelligence (AI) algorithm. The algorithm assigns a patient’s ECG male pattern probability on a scale of 0 (female) to 1 (male). In the primary analysis, done separately for transgender women (TGW) and transgender men (TGM), 12-lead ECGs were used to estimate the male pattern probability before and after GAHT. In a subanalysis, only patients with both pre- and post-GAHT EGCs were included. Further, the autopopulated PR, QRS, and QTc intervals were compared before and after GAHT. Among TGW (n = 86), the probability (mean ± SD) of an ECG male pattern was 0.84 ± 0.25 in the pre-GAHT group, and it was lowered to 0.59 ± 0.36 in the post-GAHT group (n = 173, P < 7.8 × 10−10). Conversely, among TGM, male pattern probability was 0.16 ± 0.28 (n = 47) in the pre-GAHT group, and it was higher at 0.41 ± 0.38 in the post-GAHT group (n = 53, P < 2.4×10−4). The trend persisted in the subanalysis. Furthermore, both the PR (P = 5.68 × 10−4) and QTc intervals (P = 6.65×10−6) prolonged among TGW. Among TGM, the QTc interval shortened (P = 4.8 × 10−2). Conclusion Among TG, GAHT is associated with ECG changes trending towards gender congruence, as determined by the AI algorithm and ECG intervals. Prospective studies are warranted to understand GAHT effects on cardiac structure and function.
Closing the gap between biology and classification in splenic B‐cell lymphomas
Blombery, Piers , Ferry, Judith A. , Ondrejka, Sarah L. , Seymour, John F. , Zamò, Alberto , Tzankov, Alexandar , Zamò, Alberto , Tzankov, Alexandar , Jong, Daphne de , Hsi, Eric D.

Mayo Clinic

Histopathology | October 15, 2024 | Volume: 86 | Issue: 1 | Pages: 69-78

10.1111/his.15323 | PMID 39403047 Get It

The mature splenic B‐cell lymphomas are an enigmatic group of lymphoid neoplasms that have long caused significant difficulty for the practicing pathologist due to overlapping diagnostic features among entities and the decreasing availability of splenic tissue for assessment. While some entities have highly characteristic and specific clinicopathological features (e.g. hairy cell leukaemia), others are substantially more difficult to recognise (e.g. splenic diffuse red pulp lymphoma). At the same time, classification systems have been evolving, resulting in multiple changes to the boundaries among these entities and even the existence of some entities in their own right. Moreover, unbiased multi‐omic interrogation (whole genome/transcriptome sequencing, methylome) of the splenic B‐cell lymphomas over the past decade has given us significant insights into the underling biology of these neoplasms. We present a clinicopathological perspective on the historical, current and future state of the diagnosis and classification of splenic B‐cell lymphomas integrating multi‐omic data and highlighting areas of focus for the field in order to continue to strive to improve patient outcomes through accurate diagnosis.
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
Dulai, Parambir S. , Balmert, Lauren C. , Sadler, Charlotte , Raffals, Laura E. , Kochhar, Gursimran , Lindholm, Peter , Toups, Gary, Rosas, Libeth, Narula, Neeraj , Jairath, Vipul , Honap, Sailish , Scholtens, Denise M., Jairath, Vipul , Jairath, Vipul , Adusumalli, Jayanth , Dryden, Gerald W. , Russ, Kirk , Toups, Gary N, Narula, Neeraj , Jairath, V , Honap, Sailish , Peyrin-Biroulet, Laurent , Hanauer, Stephen B , Jairath, V , Jairath, Vipul , Buckey, Jay C. , Peyrin‐Biroulet, Laurent , Sands, Bruce E , Hanauer, Stephen B. , Siegel, Corey A

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 15, 2024 | Volume: 60 | Issue: 11-12 | Pages: 1512-1524

10.1111/apt.18326 | PMID 39403018 Get It

ABSTRACTBackgroundPatients with ulcerative colitis (UC) who are hospitalised for acute severe flares represent a high‐risk orphan population.AimTo provide guidance for clinical trial design methodology in these patients.MethodsWe created a multi‐centre consortium to design and conduct a clinical trial for a novel therapeutic intervention (hyperbaric oxygen therapy) in patients with UC hospitalised for moderate–severe flares. During planning, we identified and addressed specific gaps for inclusion/exclusion criteria; disease activity measures; pragmatic trial design considerations within care pathways for hospitalised patients; standardisation of care delivery; primary and secondary outcomes; and sample size and statistical analysis approaches.ResultsThe Truelove‐Witt criteria should not be used in isolation. Endoscopy is critical for defining eligible populations. Patient‐reported outcomes should include rectal bleeding and stool frequency, with secondary measurement of urgency and nocturnal bowel movements. Trial design needs to be tailored to care pathways, with early intervention focused on replacing and/or optimising responsiveness to steroids and later interventions focused on testing novel rescue agents or strategies. The PRECIS‐2 framework offers a means of tailoring to local populations. We provide standardisation of baseline testing, venous thromboprophylaxis, steroid dosing, discharge criteria and post‐discharge follow‐up to avoid confounding by usual care variability. Statistical considerations are provided given the small clinical trial nature of this population.ConclusionWe provide an outline for framework decisions made for the hyperbaric oxygen trial in patients hospitalised for UC flares. Future research should focus on the remaining gaps identified.
DICER1 -Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Schultz, Kris Ann P. , Nelson, Alexander T. , Mallinger, Paige, Harris, Anne K. , Kamihara, Junne , Baldinger, Shari , Chen, Kenneth , Pond, Dinel , Hatton, Jessica N. , Dybvik, Anna, Perrino, Melissa R. , Ami, Tal Ben , Su, Yan , Duan, Cuihai , Watson, David , Field, Amanda L., Carr, Ann G. , Schneider, Dominik T. , Schoettler, Peter , Dehner, Louis P. , Mallinger, Paige H R , Chen, Kenneth S , Dybvik, Anna G , Mitchell, Sarah G , Perrino, Melissa R , Ben-Ami, Tal , Kachanov, Denis , Su, Yan , Duan, Chao , Olson, Damon R , Watson, Dave , Field, Amanda L , Harney, Laura A , Garrity Carr, Ann , Frazier, A Lindsay , Schneider, Dominik T , Wilson, David B , MacFarland, Suzanne P , Schoettler, Peter J , Bauer, Andrew J , Dehner, Louis P , Hill, Dana Ashley , Stewart, Douglas R , Messinger, Yoav H , Harris, Anne K , Olson, Damon R. , Wilson, David B. , Messinger, Yoav H.

Mayo Clinic

Clinical Cancer Research | October 14, 2024 | Volume: 30 | Issue: 24 | Pages: 5681-5692

10.1158/1078-0432.ccr-24-1532 | PMID 39400264 Get It

Abstract Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available. Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study. Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli–Leydig cell tumor at a median age of 14 years (range: 11 months–66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli–Leydig cell tumors were diagnosed before 4 years of age. Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.